Table 2 Flagellin as an anti-tumor agent
Treatment | Model/route | Effect | References |
|---|---|---|---|
Flagellin+D2F2 tumor cells | Mice/s.c. | Increased IFN-γ/IL-4 ratio, decreased frequency of Treg cells, significant reduction of tumor growth, CD8+ cytotoxic immune response | |
Flagellin+CpG motifs | Mice/s.c. | Promoted Th1 polarization, synergism between TLR5 and TLR9, complete remission of tumor growth | |
Flagellin treatment | Mice/i.p. | Protection against radiation, induction of radioprotective genes | |
TLR5 activation on breast cancer cells | Mice/i.v., mammary fat pads | Neutrophil infiltration in vivo, increased autophagy protein MAP1S in cancer cells, autophagy of cancer cells, inhibited tumor growth in vivo | |
Salmonella enteritidis serovar Typhimurium infection | In vitro | Apoptosis of adenocarcinomic human alveolar basal epithelial cells A549 in vitro | |
Flagella-based MUC1 vaccines | Balb/c, or human MUC1 transgenic mice | Flagellin increased higher efficiency of therapeutic activity of MUC1-based vaccines, significant reduction in size and growth rate of the tumor, lowered number of metastases, expanded life span of vaccinated mice | |
Flagellin+glucose-regulated protein 170 (Grp170) | Mice | Protection against melanoma, colon and prostate cancer, induction of potent CD8+ T-cell responses | |
Flagellin+E6/E7 peptide of papillomavirus | Mice/s.c. | Elicitation of tumor-specific IFN-γ producing CD8+T cells, retarded in vivo tumor growth, prolonged survival | |
Flagellin-derived TLR5 agonist, CBLB502 | Mice/i.v. | Protected mice from tumor death, increased NK cell and CD8+ cytotoxic activities, clinical trial in patients with advanced solid tumors is currently ongoing | |
Flagellin+P10 peptide of Paracoccidioides brasiliensis | Mice/i.n. | Activation of tumor-specific CD4+ T lymphocytes, marked reduction of lung nodules, significant increase in survival, protection against metastatic melanoma growth after adoptive transfer |
